Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

FDA Approves Breast-Cancer Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 06:05pm CET

--Drug packs Roche's Herceptin with chemotherapy agent

--Drug approved for use as a first-line, or initial treatment for advanced breast cancer

WASHINGTON--The U.S. Food and Drug Administration Friday approved a powerful new type of drug that will be marketed by Roche Holding AG (ROG.VX, RHHBY) to treat breast cancer.

The drug called, Kadcyla, combines Roche's existing cancer drug, Herceptin, with a powerful chemotherapy agent, and is meant to treat certain types of breast cancer that have spread to other parts of the body.

Herceptin targets a protein called HER2 found on tumors in about 20% to 25% of breast-cancer patients. The two other components of Kadcyla, both developed by ImmunoGen Inc. (>> ImmunoGen, Inc.), are a chemotherapy agent called emtansine that is too potent to be delivered as a conventional medicine, and a linker that connects the two drugs. Herceptin then delivers the package to the tumor cell, where it releases the toxic cargo to kill the cancer.

The FDA's approval of Kadcyla, which was previously known as T-DM1, triggers a $10.5 million payment to ImmunoGen by Roche. ImmunoGen will also receive royalties on sales of up to 5%.

Analysts said the approval was broader than expected. The drug can be marketed for initial treatment rather than just in patients who've tried other therapies, creating a "significantly larger patient population," said Simos Simeondis, an analyst at Cowen and Company.

Roche's Genentech unit said Kadcyla will be available to patients in about two weeks. The drug will be priced at $9,800 a month. The company said there will be a patient-assistance program to help pay for the product.

Agents like Kadcyla are called antibody-drug conjugates and they are the focus of intense interest in the pharmaceutical industry. Roche's Genentech unit has 25 such agents under development for different cancers, including eight in human studies.

The first such agent to gain FDA approval was Seattle Genetics Inc.'s (>> Seattle Genetics, Inc.) Adcetris, for Hodgkin's Lymphoma and another rare cancer. That company and ImmunoGen are each collaborating with big pharmaceutical firms including Bayer AG (BAYRY, BAYN.XE), Eli Lilly & Co. (>> Eli Lilly & Co.), GlaxoSmith Kline PLC (GSK, GSK.LN), Pfizer Inc. (>> Pfizer Inc.), Sanofi (>> Sanofi SA) to develop several types of new cancer drugs.

The approval of Kadcyla was based on a study of about 1,000 women with HER2-positive breast cancer who had been treated previously with Herceptin and a traditional chemotherapy drug. About half of the women were then treated with T-DM1 and the other half were treated with a combination of Xeloda, another Roche drug, and GlaxoSmithKline's Tykerb. The study showed women receiving Kadcyla lived for an average of 31 months, which was about six months longer than women being treated with Xeloda and Tykerb.

However, like other cancer drugs Kadcyla has the potential to cause serious and life-threatening side effects from liver damage or heart problems. The drug can also cause severe birth defects so doctors need to make sure women of child-bearing age aren't pregnant before administering the product.

--Joseph Walker contributed to this story.

Write to Jennifer Corbett Dooren at jennifer.corbett@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ROCHE HOLDING LTD.
01/19 FOUNDATION MEDICINE : Announces Executive Leadership Transition
01/19 GSK grabs Astra executive to replace pharma head
01/19 EISAI : acquires manufacturing rights for API from Roche to treat insomnia
01/19 ROCHE : Extended FDA Review for Lilly/Incyte's Olumiant (baricitinib) in Rheumat..
01/18 Global Influenza Market Has Been Accelerated USD 6.87 Billion in 2020
01/18 ROCHE : FDA Grants Genentech's Cancer Immunotherapy Tecentriq (Atezolizumab) Pri..
01/18 Drugmakers in Davos shift focus to chronic diseases of poor
01/17 ROCHE : Multiplex System Addresses IHC Needs
01/16 Global Lycopene Market 2017 - DSM, BASF, NIPPON, Kagome, Bayer, KIRIN, Roche ..
01/13 ROCHE : Johnson & Johnson and Alstrom Syndrome UK Address Hot Topic of Paediatri..
More news
Sector news : Pharmaceuticals - NEC
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
01/19 GSK grabs Astra executive to replace pharma head
01/19DJGLAXOSMITHKLINE : Global Pharmaceuticals President Abbas Hussain to Leave -- Upd..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/18 Astra's Mystic Mystery And Other Surprises In Store
01/18 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2016 Update
01/17 Even A $100M Series A Can't Save The Medtech Venture Climate
01/17 AnaptysBio Sets Terms For $60 Million IPO
01/13 BIOTECHS : What The 'Trump Dump' And CVS's EpiPen Move May Mean
Advertisement
Financials ( CHF)
Sales 2016 51 095 M
EBIT 2016 17 589 M
Net income 2016 11 243 M
Debt 2016 11 033 M
Yield 2016 3,63%
P/E ratio 2016 18,28
P/E ratio 2017 16,44
EV / Sales 2016 4,22x
EV / Sales 2017 3,93x
Capitalization 204 725 M
More Financials
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 282  CHF
Spread / Average Target 19%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.1.29%203 230
JOHNSON & JOHNSON-0.44%312 045
PFIZER INC.-1.39%194 369
NOVARTIS AG-3.71%189 507
MERCK & CO., INC.3.91%168 654
SANOFI-0.52%105 178
More Results